Cargando…
2337. Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial
BACKGROUND: Currently circulating Omicron subvariants contain mutations permitting evasion of neutralization with prototype vaccines. Novel Omicron BA.1 (NVX-CoV2515) and Omicron BA.5 (NVX-CoV2540) subvariant-specific vaccines were tested alone or as bivalent preparations combined with the prototype...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679145/ http://dx.doi.org/10.1093/ofid/ofad500.1959 |